Valdecoxib provides effective pain relief following acute ankle sprain

Journal of International Medical Research

Volumn 34, Issue 5, 2006, Pages 456-467

  Diaz, J A ^a   Cuervo, C ^b   Valderrama, Ana M ^c,d   Kohles, J ^c  

^a Clinica Medellin   (Colombia)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c Pfizer Global Pharmaceuticals   (United States)

^d PFIZER INC   (United States)

Author keywords

'Cyclooxygenase (COX) 2 inhibitors; Ankle sprain; Diclofenac; Pain; Valdecoxib

Indexed keywords

DICLOFENAC; VALDECOXIB;

ADULT; ALLERGIC RASH; ANALGESIA; ANKLE PAIN; ANKLE SPRAIN; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; FEMALE; FINGER FRACTURE; GASTRITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

EID: 33751024793     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400502     Document Type: Article

References (41)

1. Renstrom PA, Konradsen L: Ankle ligament injuries. Br J Sports Med 1997; 31: 11-20.
2. Braun BL: Effects of ankle sprain in a general clinic population 6 to 18 months after medical evaluation. Arch Fam Med 1999; 8: 143-148.
3. Verhagen RA, de Keizer G, van Dijk CN: Longterm follow-up of inversion trauma of the ankle. Arch Orthop Trauma Surg 1995; 114: 92-96.
4. Yeung MS, Chan KM, So CH, Yuan WY: An epidemiological survey on ankle sprain. Br J Sports Med 1994; 28: 112-116.
5. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC: Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 1997; 283: 1069-1075.
6. Ogilvie-Harris DJ, Gilbart M: Treatment modalities for soft tissue injuries of the ankle: a critical review. Clin J Sport Med 1995; 5: 175-186.
7. Bouchier-Hayes TA: Naproxen sodium and piroxicam in acute musculo-skeletal disorders. Br J Sports Med 1984; 18: 80-83.
8. Duncan JJ, Farr JE: Comparison of diclofenac sodium and aspirin in the treatment of acute sports injuries. Am J Sports Med 1988; 16: 656-659.
9. Ekman EF, Fiechtner JJ, Levy S, Fort JG: Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop 2002; 31: 445-451.
10. Ekman EF, Ruoff G, Kuchl K, Ralph L, Hormbrey P, Fiechtner JI, et al: The COX-2 specific inhibitor valdecoxib versus tramadol in acute ankle sprain: a multicenter, randomized, controlled trial. Am J Sports Med 2006; 34: 945-955.
11. Heere LP: Piroxicam in acute musculoskeletal disorders and sport injuries. Eur J Rheumatol Inflamm 1987; 8: 60-64.
12. Petrella R, Ekman EF, Schuller R, Fort JG: Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial. Clin J Sport Med 2004; 14: 225-231.
13. Slatyer MA, Hensley MJ, Lopert R: A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study. Am J Sports Med 1997; 25: 544-553.
14. Goldstein IL, Eisen GM, Agrawal N, Stenson WF, Kent ID, Verburg KM: Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 2004; 20: 527-538.
15. Goldstein IL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD: A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther 2003; 18: 125-132.
16. Harris SI, Kass M, Hubbard RC, Goldstein JL: Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001; 23: 1422-1428.
17. Pavelka K, Recker DP, Verburg KM: Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 2003; 42: 1207-1215.
18. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM: Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002; 14: 1101-1111.
19. Green D, Davies RO, Holmes GI, Kohl H, Lee RB, Reynolds N, et al: Effects of diflunisal on platelet function and fecal blood loss. Clin Pharmacol Ther 1981; 30: 378-384.
20. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40: 124-132.
21. Leese PT, Recker DP, Kent JD: The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2003; 43: 504-513.
22. Leese PT, Talwalker S, Kent JD, Recker DP: Valdecoxib does not impair platelet function. Am J Emerg Med 2002; 20: 275-281.
23. Bensen W, Weaver A, Espinoza L, Zhao WW, Riley W, Paperiello B, et al: Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford) 2002; 41: 1008-1016.
24. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP: Randomized placebo-controlled trial comparing efficacy and scifety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002; 51: 530-537.
25. Makarowski W, Zhao WW, Bevirt T, Recker DP: Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002; 10: 290-296.
26. Camu F, Beecher T, Recker DP, Verburg KM: Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002; 9: 43-51.
27. Daniels SE, Desjardins PJ, Talwalker S, Recker DP, Verburg KM: The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc 2002; 133: 611-621.
28. Fricke J, Varkalis J, Zwillich S, Adler R, Forester E, Recker DP, et al: Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 2002; 9: 89-97.
29. Reynolds LW, Hoo RK, Brill RJ, North J, Recker DP, Verburg KM: The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J Pain Symptom Manage 2003; 25: 133-141.
30. Skoutakis VA, Carter CA, Mickle TR, Smith VH, Arkin CR, Alissandratos J, et al: Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflarnmatory agent. Drug Intell Clin Pharm 1988; 22: 850-859.
31. Small RE: Diclofenac sodium. Clin Pharm 1989; 8: 545-558.
32. Todd PA, Sorkin EM: Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244-285.
33. Moran M: An observer-blind comparison of diclofenac potassium, piroxicam and placebo in the treatment of ankle sprains. Curr Med Res Opin 1990; 12: 268-274.
34. Moran M: Double-blind comparison of diclofenac potassium, ibuprofen and placebo in the treatment of ankle sprains. J Int Med Res 1991; 19: 121-130.
35. Verstraeten A, Bakshi R: Diclofenac potassium for the treatment of traumatic joint distortions: an open multicentre study. J Int Med Res 1991; 19: 165-170.
36. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1). June 1996. Available at: www.ich.org/MediaServer.jser?@_ID=482&@_MODE=GLB (last accessed 23 May 2006).
37. Forouzonfar T, Weber WE, Kemler M, van Kleef M: What is a meaningful pain reduction in patients with complex regional pain syndrome type 1? Clin J Pain 2003; 19: 281-285.
38. Jensen MP, Chen C, Brugger AM: Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain 2003; 4: 407-414.
39. Food and Drug Administration Center for Drug Evaluation and Research. Bextra (Valdecoxib). Available at: www.fda.gov/Cder/foi/nda/2001/ 21-341_Bextra.htm (last accessed 1 September 2006).
40. Jenkins JK, Seligman PJ: Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. Food and Drug Administration. Available at: www.fda.gov/cder/drug/ infopage/COX2/NSAIDdecisionMemo.pdf (last accessed 1 September 2006).
41. Mahler P, Mahler F, Duruz H, Ramazzina M, Liguori V, Moutone G: Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin, for the treatment of sprains, strains and contusions. Drugs Exp Clin Res 2003; 29: 45-52.